Loading Events

« All Webinars

“Platelet-ing It Safe: Dual Antiplatelet Therapy for Special Populations with Coronary Artery Disease”

HealthTrust presents…“Platelet-ing It Safe: Dual Antiplatelet Therapy for Special Populations with Coronary Artery Disease”

Download the content.

Please Note: Continuing education credit is only available to those attending the session live. CE credit is not available when accessing the program on demand.

In patients undergoing percutaneous coronary intervention, dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is indicated to reduce cardiovascular risks and minimize stent thrombosis. Certain populations on DAPT may have increased bleeding or ischemic risks due to patient characteristics and comorbidities, such as genetic polymorphisms and concomitant anticoagulant use. The updated 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization recommends evaluating patient-specific factors to guide P2Y12 inhibitor selection and reduce bleeding risks without increasing ischemic events. This presentation will review current literature evaluating DAPT strategies and their clinical applications in special patient populations.

Learning Objectives for Pharmacists & Nurses   |  At the end of this session, participants should be able to:

  1. Recall advantages, potential risks, and characteristics of P2Y12 inhibitors.
  2. Recognize guideline recommendations for the efficacy and bleeding risks associated with P2Y12 inhibitors used in dual antiplatelet therapy for special populations
  3. Identify appropriate recommendations for P2Y12 inhibitor selection in an antiplatelet regimen based on patient specific recommendations

Learning Objectives for Pharmacy Techs   |  At the end of this session, participants should be able to:

  1. Recall available P2Y12 inhibitors utilized in dual antiplatelet therapy after percutaneous coronary intervention
  2. Identify safety considerations with P2Y12 inhibitors
  3. Recognize potential access barriers for patients receiving P2Y12 inhibitors


Jahnavi Yetukuri, PharmD  |  PGY-1 Pharmacy Resident  |  Atlantic Health System  |  Morristown, NJ

Target Audience: Pharmacists, Pharmacy Techs & Nurses

CE Credit: Approved for Pharmacists, Pharmacy Techs & Nurses

This program is approved for CPEs by the Accreditation Council for Pharmacy Education (ACPE). Attendees of this program may earn 1.0 CPE Contact Hours. Belmont University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Numbers for this activity are 0863-9999-23-050-L01-P (Pharmacists) and 0863-9999-23-050-L01-T (Techs). The activity is approved for 1 hour (.1 CEUs) of continuing education credit for nurses, pharmacists and pharmacy techs who attend the webinar and complete the online evaluation. Pfiedler Education is a division of AORN, provider approved by the California Board of Registered Nursing, Provider Number CEP13019, for 1 contact hour. 1.0 contact hours approved for Nurses.

Register here.

Note about CE credit: If you plan to obtain credit for a live session, stay until the end of the presentation to receive the verification code you will need to obtain the continuing education credit. CE credit is individual. No group credit is available. Each person must register for a webinar and attend the webinar in its entirety in order to receive an email after the event with instructions on how to apply for continuing education credit. Attendees should not share the code or forward the email to others who did not actually attend the program. If they are not able to be verified on our webinar provider reports and registration list they will not receive credit. If you are joining only by phone, you will not be eligible for credit. You must also log in and join the visual portion of the webinar to be part of our CE provider-required reporting.